Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis

Dominik Lautsch; Adnan Alsumali; Euan McLeod; Yuting Kuang; Jing He; Rajpal Singh; Arianna Nevo; Urs Arnet; Jennifer Uyei; Swapnil Rajpathak

doi:10.1007/s13300-020-00975-y

Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis

Diabetes Ther. 2021 Jan;12(1):389-418. doi: 10.1007/s13300-020-00975-y. Epub 2020 Dec 12.

Authors

Dominik Lautsch¹, Adnan Alsumali², Euan McLeod³, Yuting Kuang⁴, Jing He⁴, Rajpal Singh⁵, Arianna Nevo⁴, Urs Arnet², Jennifer Uyei⁴, Swapnil Rajpathak²

Affiliations

¹ Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. dominik.lautsch@merck.com.
² Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
³ Pfizer, Inc., Tadworth, UK.
⁴ IQVIA, Inc., San Francisco, CA, USA.
⁵ IQVIA, Inc., Mumbai, India.

Abstract

Introduction: Current guidelines recommend adding an oral antihyperglycemic agent (AHA) to metformin in patients with type 2 diabetes mellitus (T2DM) uncontrolled on metformin. Recent randomized clinical trials (RCTs) have demonstrated that adding dual AHAs instead of a single AHA provided more effective glycemic control. However, the comparative efficacy of approved single and dual initiation strategies is unknown. Therefore, we conducted a Bayesian network meta-analysis to compare the efficacy of dual and single add-on oral AHAs in patients uncontrolled on metformin.

Methods: A systematic literature review of RCTs was conducted following Cochrane and ISPOR guidelines. MEDLINE, Embase, and CENTRAL were searched from inception to November 19, 2019. Approved oral doses of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists in single or dual initiation therapies were indirectly compared. Outcomes focused on efficacy and included mean change from baseline in hemoglobin A1c (HbA1c), weight, systolic blood pressure (SBP), diastolic blood pressure, and achieving HbA1c target < 7% at 24-26 weeks. Fixed and random effects models with Markov chain Monte Carlo simulations were used.

Results: Of 1955 unique records screened, 25 RCTs (14,264 participants) were included. In patients uncontrolled on metformin, dual AHA added to metformin had statistically significant or a trend of greater reduction in HbA1c compared to single AHAs, with ertugliflozin + sitagliptin showing the greatest improvement. Statistically significant reductions in weight and SBP were observed with ertugliflozin + sitagliptin, ertugliflozin, or canagliflozin compared to single initiation DPP-4 inhibitors.

Conclusion: For reduction of HbA1c, weight, and SBP in patients uncontrolled on metformin, add-on dual AHAs showed greater improvement compared to single AHAs. These findings can further inform the treatment of T2DM patients uncontrolled on metformin.

Keywords: Dual initiation; Network meta-analysis; Oral antihyperglycemic agent; Type 2 diabetes.